Bio-Works Fuels Growth with Key Orders and Capital Raise
January 2, 2026, 9:34 pm
Bio-Works Technologies solidifies market presence. New SEK 4 million WorkBeads orders from a key Indian client underscore robust biopharmaceutical purification demand. These orders bolster future revenue. Simultaneously, the firm launched its fifth TO 2 warrants exercise period. This strategic capital raise generates funding for ongoing operations. It also impacts future share structure, with potential 16% dilution. Bio-Works targets sustained growth, global market expansion, and enhanced profitability within the competitive biotech sector. The company navigates stringent regulatory frameworks. These dual developments define Bio-Works' aggressive strategic push. It reinforces its position as a vital biotech partner.
Bio-Works Technologies AB recently announced significant commercial success. The company secured two substantial orders. A recurring customer in India placed these orders. The total value reached approximately SEK 4 million. This strengthens Bio-Works' financial outlook for the coming year. Deliveries are scheduled for the first and second quarters of 2026. This confirms robust demand for the company's specialized products.
The orders specifically involve WorkBeads 100S and WorkBeads 100Q. These products are crucial for biopharmaceutical manufacturing. They provide scalable and cost-efficient affinity solutions. Their primary function is biomolecule purification. This process is essential in developing and producing vital biopharmaceutical drugs. Bio-Works enables biotech companies to achieve their purification goals. The company supports customers from laboratory research through commercial production. This market segment is growing rapidly. Bio-Works aims to be a trusted, dynamic partner in this evolving industry.
These commercial wins are strategic. They demonstrate the strength of Bio-Works' customer relationships. They also reflect increasing global demand for WorkBeads products. The orders align with Bio-Works' ambition. The company seeks to build a profitable and scalable business model. Its operational headquarters, including R&D and manufacturing, are in Uppsala, Sweden. Bio-Works supplies its products globally. It uses both direct sales and an extensive distributor network. This network spans Europe, North America, and Asia. The company maintains ISO 9001:2015 quality certification. This ensures high product standards.
Parallel to its commercial achievements, Bio-Works is actively managing its capital structure. The company initiated the fifth exercise period for its series TO 2 warrants. This period commenced on January 2, 2026. It concludes on January 16, 2026. These warrants were issued during a rights issue in August 2024. This is a critical step in Bio-Works' financial strategy.
Holders of TO 2 warrants can subscribe for new shares. Each warrant entitles the holder to one new share. The subscription price is SEK 1 per share. This mechanism provides a clear path for investors. They can convert their warrants into equity. Bio-Works structured these warrants with eleven exercise periods. These periods occur quarterly. They run from early 2025 through the third quarter of 2027. Each warrant can be exercised only once.
Previous exercise periods have seen significant participation. A total of 20,265,542 warrants were already exercised. This indicates strong investor confidence. Currently, 18,714,248 warrants remain outstanding. Their full exercise will impact Bio-Works' share capital. The number of shares will increase. Total shares will reach approximately 116.9 million. Share capital will also rise significantly. This full exercise results in an approximate 16.0 percent dilution. This dilution affects both capital and voting rights. Such financial maneuvers are common for growth-focused companies. They secure necessary capital for expansion.
Bio-Works navigates a complex regulatory environment. The company adheres to the EU Market Abuse Regulation. Strict rules apply to information disclosure. Further, the exercise of warrants carries jurisdictional restrictions. Distribution in countries like the United States, Australia, and Japan is limited. These limitations ensure compliance with diverse securities laws. Bio-Works also addresses the Swedish FDI Act. This act requires screening of foreign direct investments. Investors crossing specific voting thresholds must notify authorities. This illustrates the intricate legal framework.
These dual developments highlight Bio-Works' strategic direction. The company is actively expanding its market reach. It is strengthening its product portfolio. Simultaneously, it is optimizing its financial resources. The WorkBeads orders validate Bio-Works' product quality and market fit. The warrant exercise provides essential capital for ongoing operations and future initiatives. Bio-Works is listed on the Spotlight Stock Market ("BIOWKS"). Its actions reflect a disciplined approach. The company aims for long-term growth and sustained profitability. Bio-Works continues to solidify its position. It remains a key player in the global biopharmaceutical purification market.
Bio-Works Technologies AB recently announced significant commercial success. The company secured two substantial orders. A recurring customer in India placed these orders. The total value reached approximately SEK 4 million. This strengthens Bio-Works' financial outlook for the coming year. Deliveries are scheduled for the first and second quarters of 2026. This confirms robust demand for the company's specialized products.
The orders specifically involve WorkBeads 100S and WorkBeads 100Q. These products are crucial for biopharmaceutical manufacturing. They provide scalable and cost-efficient affinity solutions. Their primary function is biomolecule purification. This process is essential in developing and producing vital biopharmaceutical drugs. Bio-Works enables biotech companies to achieve their purification goals. The company supports customers from laboratory research through commercial production. This market segment is growing rapidly. Bio-Works aims to be a trusted, dynamic partner in this evolving industry.
These commercial wins are strategic. They demonstrate the strength of Bio-Works' customer relationships. They also reflect increasing global demand for WorkBeads products. The orders align with Bio-Works' ambition. The company seeks to build a profitable and scalable business model. Its operational headquarters, including R&D and manufacturing, are in Uppsala, Sweden. Bio-Works supplies its products globally. It uses both direct sales and an extensive distributor network. This network spans Europe, North America, and Asia. The company maintains ISO 9001:2015 quality certification. This ensures high product standards.
Parallel to its commercial achievements, Bio-Works is actively managing its capital structure. The company initiated the fifth exercise period for its series TO 2 warrants. This period commenced on January 2, 2026. It concludes on January 16, 2026. These warrants were issued during a rights issue in August 2024. This is a critical step in Bio-Works' financial strategy.
Holders of TO 2 warrants can subscribe for new shares. Each warrant entitles the holder to one new share. The subscription price is SEK 1 per share. This mechanism provides a clear path for investors. They can convert their warrants into equity. Bio-Works structured these warrants with eleven exercise periods. These periods occur quarterly. They run from early 2025 through the third quarter of 2027. Each warrant can be exercised only once.
Previous exercise periods have seen significant participation. A total of 20,265,542 warrants were already exercised. This indicates strong investor confidence. Currently, 18,714,248 warrants remain outstanding. Their full exercise will impact Bio-Works' share capital. The number of shares will increase. Total shares will reach approximately 116.9 million. Share capital will also rise significantly. This full exercise results in an approximate 16.0 percent dilution. This dilution affects both capital and voting rights. Such financial maneuvers are common for growth-focused companies. They secure necessary capital for expansion.
Bio-Works navigates a complex regulatory environment. The company adheres to the EU Market Abuse Regulation. Strict rules apply to information disclosure. Further, the exercise of warrants carries jurisdictional restrictions. Distribution in countries like the United States, Australia, and Japan is limited. These limitations ensure compliance with diverse securities laws. Bio-Works also addresses the Swedish FDI Act. This act requires screening of foreign direct investments. Investors crossing specific voting thresholds must notify authorities. This illustrates the intricate legal framework.
These dual developments highlight Bio-Works' strategic direction. The company is actively expanding its market reach. It is strengthening its product portfolio. Simultaneously, it is optimizing its financial resources. The WorkBeads orders validate Bio-Works' product quality and market fit. The warrant exercise provides essential capital for ongoing operations and future initiatives. Bio-Works is listed on the Spotlight Stock Market ("BIOWKS"). Its actions reflect a disciplined approach. The company aims for long-term growth and sustained profitability. Bio-Works continues to solidify its position. It remains a key player in the global biopharmaceutical purification market.